Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 21,303

Document Document Title
WO/2016/106625A1
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use ...  
WO/2016/098061A1
Described herein are methods of treating and preventing muscle wasting and muscle loss, using adherent stromal cells and conditioned medium produced thereby.  
WO/2016/097299A1
Compound for treatment of myotonic dystrophy type The present invention relates to a compound, or a salt thereof, and a pharmaceutical composition comprising said compound, or a salt thereof, for use in the prevention and/or treatment of...  
WO/2016/092439A1
The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age- related sarcopenia. Especially, the myostatin or activin antagon...  
WO/2016/092139A1
The invention relates to a drug that permits the effective treatment of motor neurone diseases. In particular, the invention relates to a composition comprising a) a compound or any of the pharmaceutically acceptable salts thereof, where...  
WO/2016/088797A1
Provided are: a nucleic acid that reduces toxicity caused by abnormal accumulation of an RNA-binding protein in cells and is usable for preventing or treating a neurodegenerative disease; and a prophylactic or therapeutic agent for a neu...  
WO/2016/089304A1
The present invention provides a method of treating one or more sodium channel related diseases or disorders in an individual, including related symptoms. The method comprises administering to the individual a tetrahydropyridine derivati...  
WO/2016/086103A1
The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibros...  
WO/2016/086114A1
The present invention relates to methods and sports drink compositions for treating and/or preventing muscle weakness and/or increasing muscle strength and/or stamina in subjects in need thereof. The sports drink composition includes meg...  
WO/2016/086136A1
The invention relates to fatty acid cysteamine conjugates of a CFTR modulator, compositions comprising a fatty acid cysteamine conjugate of a CFTR modulator, and methods for using such conjugates and compositions to treat disease, such a...  
WO/2016/084816A1
Provided is a bicyclic compound having an inhibitory effect on acetyl-CoA carboxylase. A compound represented by the formula: (in the formula, each of the symbols is as defined in the specification) or a salt thereof has an inhibitory ef...  
WO/2016/084870A1
Provided is an acylaminophenyl-group-containing compound having a neuroprotective effect. Also provided is a neuroprotective agent including an acylaminophenyl-group-containing compound. A novel acylaminophenyl-group-containing compound,...  
WO/2016/084412A1
It is found that the activation of a B cell can be inhibited by TGF-beta3 produced by LAG3+ Treg. A B cell activation inhibitor comprising TGF-beta3 or a molecule having the function of TGF-beta3 and a therapeutic agent for autoimmune di...  
WO/2016/080887A1
The present invention relates to FHLl (Four-and-a-half-LIM domain 1) as a new muscle specific autoantigen. The invention provides methods for diagnosis of autoimmune muscle diseases, such as myositis, polymyositis, deimatomyositis, inclu...  
WO/2016/080516A1
The present invention provides a pharmaceutical composition containing cilnidipine or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention relates to: a dynamin-related protein 1 (Drp1) polymerization...  
WO/2016/075137A1
The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of s...  
WO/2016/075285A1
The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the ...  
WO/2016/075288A1
The present invention relates to caffeine for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising caffeine for use in the treatment of myotonic dystrophy type 1 and ...  
WO/2016/076434A1
Disclosed are a muscular dystrophy therapeutic agent using pluripotent stem cells obtained from dental pulp, and a method for producing the same. This muscular dystrophy therapeutic agent contains, as an active ingredient, cells derived ...  
WO/2016/073545A1
This invention relates to novel phenyloxadiazole benzoic acids, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods ...  
WO/2016/063933A1
Provided is a heterocyclic compound that has an excellent RBP4 reducing effect and is useful as a preventive or therapeutic drug for diseases or symptoms mediated by a rise in RBP4 or by retinol supplied by RBP4. A compound represented b...  
WO/2016/061632A1
The present invention provides an isolated or recombinant Fn14-binding protein comprising an antigen binding domain, wherein the antigen binding domain binds specifically to Fn14 or a cell expressing Fn14.  
WO/2016/059411A1
The present invention relates to the use of cannabinoids in the treatment of degenerative skeletal muscle disease. In particular the degenerative skeletal muscle disease is Duchenne muscular dystrophy (DMD). Preferably the cannabinoids a...  
WO/2016/059287A1
The present invention relates to a method of treating motor neuron diseases such as amyotrophic lateral sclerosis (ALS) using levosimendan or its active metabolite (II) as an active ingredient. Levosimendan or its active metabolite (II) ...  
WO/2016/056645A1
In the present invention, an expression vector that promotes lysosome uptake of a target nucleic acid and identifies a protein that induces degradation of an abnormal nucleic acid, or includes the genes encoding the same, has been develo...  
WO/2016/057322A1
Provided herein are deuterated compounds and compositions useful in increasing PPAR5 activity. The compounds and compositions provided herein are useful for the treatment of PPAR5 related diseases (e.g., muscular diseases, vascular disea...  
WO/2016/057656A1
Provided herein are methods for increasing PPAR5 activity and methods for treating PPARδ related diseases (e.g., mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases, and metabolic diseases).  
WO/2016/054742A1
Disclosed are apparatus and methods for producing and delivering vapour medicament. An exemplary apparatus disclosed comprises: a gas inlet for receiving a gas from a source of pressurized gas; a chamber for receiving a liquid medicament...  
WO/2016/057658A8
Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular d...  
WO/2016/057658A1
Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular d...  
WO/2016/057658A9
Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular d...  
WO/2016/052656A1
An autophagy inducing agent that comprises at least one member selected from a compound represented by structural formula (A), a compound represented by structural formula (B), and a compound represented by structural formula (C).  
WO/2016/049884A1
Provided are a conotoxin polypeptide κ-CPTx-bt105, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 16 amino acids, has a molecular weight of 1626.62 daltons, and has the full sequence ...  
WO/2016/049864A1
Disclosed are a conotoxin polypeptide κ-CPTx-bt101, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 18 amino acids, has a molecular weight of 1872.72 daltons, ...  
WO/2016/049746A1
Described are methods of producing an autologous composition useful for treatment of damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory d...  
WO/2016/049881A1
Provided are a conotoxin polypeptide κ-CPTx-bt104, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 11 amino acids, has a molecular weight of 1313.47 daltons, and has the full sequence ...  
WO/2016/049873A1
Provided are a conotoxin polypeptide κ-CPTx-bt103, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 29 amino acids, has a molecular weight of 3141.43 daltons, and has the full sequence ...  
WO/2016/049869A1
Disclosed are a conotoxin polypeptide κ-CPTx-bt102, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 15 amino acids, has a molecular weight of 1660.61 daltons, ...  
WO/2016/046759A3
The invention provides compositions and methods useful for the treatment of Friedreich's ataxia. In some embodiments, the invention provides compositions and methods useful for inhibiting the ubiquitination of frataxin.  
WO/2016/044167A1
Methods of increasing muscle strength and mobility in a subject experiencing significant physical inactivity include administering gamma linolenic acid to the subject as part of a nutritional composition containing fat and at least one o...  
WO/2016/044635A1
Methods of rehabilitation of neurological disorders, including neurological deficits associated with neurotraumas, such as stroke and traumatic brain injury, and with muscle disorders, that includes administering to a subject a MAO-B inh...  
WO/2016/044272A1
Methods of preserving muscle strength in a subject during a period of muscle disuse are provided. Methods of preserving muscle strength in a subject during a period of muscle disuse and a subsequent period of muscle recovery are also pro...  
WO/2016/041192A1
Disclosed is a use of ligustilide, comprising a use of ligustilide to improve a therapeutic benefit of a stem cell, and a use of ligustilide and a stem cell treated therewith in a stem cell treatment. Treating the stem cell via the ligus...  
WO/2016/044796A1
The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol.  
WO/2016/040801A1
The invention provides therapeutic methods comprising the administration of thymol or carvacrol, or a pharmaceutically acceptable salt or prodrug thereof. The methods are useful for modulating muscle atrophy, performance, recovery, gener...  
WO/2016/039359A1
The present invention relates to: a terpenoid derivative which is capable of activating a Keap1/Nrf2/ARE signaling pathway and has an excellent anti-inflammatory activity and an excellent cell-protecting activity; and a sustained-release...  
WO/2016/040234A1
The present invention provides a method of treating symptoms associated with Androgen Deprivation Therapy comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I: [Formula should be ...  
WO/2016/035182A1
[Problem] The purpose of the present invention is to provide a composition that is a ginsenoside composition derived from medicinal ginseng and that is particularly useful as a composition for oral use. [Solution] Provided is a compositi...  
WO/2016/035934A1
The present invention relates to a human cell model of GM1 gangliosidosis, induced pluripotent stem cells (iPSCs) thereof, a method for preparing model cells based on neural progenitor cells derived from the iPSCs, and a use for the GM1 ...  
WO/2016/030323A1
The present invention relates to the use of elafin for the treatment and/or prevention of diseases or disorders associated with an increase in troponin levels, which are non elastase dependent. The present invention in a preferred embodi...  

Matches 101 - 150 out of 21,303